<DOC>
	<DOCNO>NCT00411190</DOCNO>
	<brief_summary>Relacatib develop treatment osteoporosis , osteoarthritis possibly bone disorder . Recent result suggest relacatib interacts way body metabolise drug drug commonly prescribe intended target patient population could affect give relacatib time . The purpose study evaluate effect repeat dose administration relacatib way subject body metabolise three commonly prescribed medication osteoarthritis population : ibuprofen , acetaminophen , atorvastatin .</brief_summary>
	<brief_title>Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen , Ibuprofen And Atorvastatin</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Healthy Postmenopausal Body weight &gt; 50 kg Body mass index ( BMI ) 19 30 The subject willing able give sign date write informed consent prior admission study The subject able understand comply protocol requirement , instruction protocolstated restriction . Subjects know morphea sclerodermia Subjects history myocardial infarction . Subjects history renal/or hepatic disease unless disease successfully treat longer active ; subject evidence renal/ hepatic impairment screen physical laboratory examination . Subjects history hypertension systolic blood pressure Subjects history diabetes History regular alcohol consumption exceed 7 drinks/week ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) within 6 month screen . History use tobacco nicotinecontaining product within 6 month screen , positive urine cotinine indicative smoking screening . Positive urine drug screen include alcohol ( alcohol breath test ) screening . Positive HIV , hepatitis B virus hepatitis C virus . Donation blood excess 500 mL within 56 day prior dose History sensitivity contraindication study medication ( i.e. , relacatib , paracetamol , ibuprofen atorvastatin ) component thereof . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . Subjects judge investigator risk acute angle closure glaucoma .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>